Elucidation of Mechanisms of Radiation-Induced Endovascular Injury and Development of Treatments / Mitigators for Radiation-Induced Endothelial Cell and Vascular Dysfunction (U01)

The summary for the Elucidation of Mechanisms of Radiation-Induced Endovascular Injury and Development of Treatments / Mitigators for Radiation-Induced Endothelial Cell and Vascular Dysfunction (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Elucidation of Mechanisms of Radiation-Induced Endovascular Injury and Development of Treatments / Mitigators for Radiation-Induced Endothelial Cell and Vascular Dysfunction (U01): The NIAID Radiation/Nuclear Countermeasures Development Program supports extramural research to develop safe and effective radiological/nuclear medical countermeasures for clinical use under emergency situations. This program spans basic through applied research. The role of the endovascular network in radiation injury pathogenesis is not well understood; however, the importance of this biological system in the observed multi-organ dysfunction and failure that occurs following radiation exposure has recently been established. The purpose of the Funding Opportunity Announcement (FOA) is to provide an opportunity for academic, industry and government laboratory researchers to address gaps in the understanding of the pathophysiology of radiation injury in the vasculature, and how this damage contributes to overall mortality following radiation exposure. This funding will also advance the development of post-exposure treatment approaches targeting the vascular endothelium, with the ultimate goal of licensure of candidate medical countermeasures by the Food and Drug Administration (FDA) for the radiation/nuclear public health emergency indication.

Federal Grant Title:	Elucidation of Mechanisms of Radiation-Induced Endovascular Injury and Development of Treatments / Mitigators for Radiation-Induced Endothelial Cell and Vascular Dysfunction (U01)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AI-16-053
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.855, 93.856
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 10th, 2016
Original Application Deadline:	November 10th, 2016
Posted Date:	August 2nd, 2016
Creation Date:	August 2nd, 2016
Archive Date:	December 11th, 2016
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:	$350,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	August 2nd, 2016

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-16-053.html
Grant Announcement Contact: NIH OER Webmaster
[email protected]

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Immunobiology of Xenotransplantation (U19 Clinical Trial Not Allowed); • Partnerships for the Development of Tools to Advance Therapeutic Discovery for Select Anti...; • Immunobiology of Xenotransplantation (U01 Clinical Trial Not Allowed); • Limited Interaction Targeted Epidemiology: Epidemiology of Transmission and Treatment of H...; • Center for HIV/AIDS Vaccine Immunology (CHAVI); • Genomics of Transplantation Cooperative Research Program; • Asthma and Allergic Diseases Cooperative Research Centers
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...